The effect of different doses of sufentanil on median effective dose and BIS50 of cirprofol during hysteroscopic day surgery

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300073599

Enrollment

Unknown

Registered

2023-07-15

Start date

2023-07-15

Completion date

Unknown

Last updated

2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hysteroscopic day surgery

Interventions

Group R1:0.1ug/kg sufentanil,Sequential administration of cirprofol at an initial dose of 0.5mg/kg

Group R2:0.2ug/kg sufentanil,Sequential administration of cirprofol at an initial dose of 0.4mg/kg

Group R3:0.3ug/kg sufentanil,Sequential administration of cirprofol at an initial dose of 0.3mg/kg

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Female patients undergoing hysteroscopic day surgery 2. Patients aged 18-60 years; 3. BMI 18-24 kg/m2; 4. Patients with ASA grade I-II;

Exclusion criteria

Exclusion criteria: 1. Severe Cardiopulmonary Disease 2. Long term history of taking psychotropic drugs and cognitive impairment 3. Have a history of drug and alcohol abuse 4. Allergies or contraindications to drugs and their components 5. Participated in other clinical trials as a subject within the past 3 months

Design outcomes

Primary

Measure	Time frame
Median effective dose;95% confidence limits;BIS50;	—

Secondary

Measure	Time frame
Adverse reactions;Resuscitation room stay time;	—

Countries

China

Contacts

Public ContactWu Duozhi

Hainan General Hospital

13976674619@163.com+86 131 7898 0800

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026